Bullous Pemphigoid

Common Name(s)

Bullous Pemphigoid

Bullous pemphigoid is a skin disorder characterized by large blisters. The blisters are usually located on the arms, legs, or middle of the body. About one-third of persons with bullous pemphigoid also develop blisters in the mouth. The blisters may break open and form ulcers or open sores. It usually occurs in elderly persons and is rare in young people. Symptoms come and go. In most patients, the condition goes away within 6 years. The cause is not known, but may be related to immune system disorders.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Bullous Pemphigoid" for support, advocacy or research.

Logo
International Pemphigus and Pemphigoid Foundation

The IPPF provides direct access to innovative and effective support that promotes the very best health care, improves quality of life, stimulates community resources, advocates for favorable government policies, accelerates the pace of scientific discovery and is the world’s best source of information on pemphigus and pemphigoid. We are compassionate in understanding, tireless in service, and relentless in advocating. One person at a time, we make a difference, building a community of care and hope.

Last Updated: 8 Mar 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Bullous Pemphigoid" for support, advocacy or research.

Logo
International Pemphigus and Pemphigoid Foundation

The IPPF provides direct access to innovative and effective support that promotes the very best health care, improves quality of life, stimulates community resources, advocates for favorable government policies, accelerates the pace of scientific discovery and is the world’s best source of information on pemphigus and pemphigoid. We are compassionate in understanding, tireless in service, and relentless in advocating. One person at a time, we make a difference, building a community of care and hope.

http://www.pemphigus.org/

Last Updated: 8 Mar 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Bullous Pemphigoid" returned 209 free, full-text research articles on human participants. First 3 results:

Bullous pemphigoid and neurological disease: statistics from a dermatology service.
 

Author(s): Monica Jidid Mateus Tarazona, Amanda Nascimento Cavalleiro de Macedo Mota, Alexandre Carlos Gripp, Natasha Unterstell, Aline Lopes Bressan

Journal: An Bras Dermatol. ;90(2):280-2.

 

Bullous pemphigoid (BP) is an autoimmune, acquired, cutaneous disease caused by the production of autoantibodies against hemidesmosomes' components in the basement membrane. The estimated incidence in Europe ranges from 7 to 43 cases per million inhabitants per year. Several studies ...

Last Updated: 2 Apr 2015

Go To URL
Mediators of mast cells in bullous pemphigoid and dermatitis herpetiformis.
 

Author(s): Agnieszka Zebrowska, Malgorzata Wagrowska-Danilewicz, Marian Danilewicz, Olga Stasikowska-Kanicka, Lilianna Kulczycka-Siennicka, Anna Wozniacka, Elzbieta Waszczykowska

Journal: Mediators Inflamm.. 2014 ;2014():936545.

 

Bullous pemphigoid (BP) and dermatitis herpetiformis (DH) are skin diseases associated with inflammation. However, few findings exist concerning the role of mast cells in autoimmune blistering disease. Skin biopsies were taken from 27 BP and 14 DH patients, as well as 20 healthy individuals. ...

Last Updated: 17 Nov 2014

Go To URL
Human eosinophils express the high affinity IgE receptor, FcεRI, in bullous pemphigoid.
 

Author(s): Kelly N Messingham, Heather M Holahan, Alexandra S Frydman, Colleen Fullenkamp, Rupasree Srikantha, Janet A Fairley

Journal:

 

Bullous pemphigoid (BP) is an autoimmune blistering disease mediated by autoantibodies targeting BP180 (type XVII collagen). Patient sera and tissues typically have IgG and IgE autoantibodies and elevated eosinophil numbers. Although the pathogenicity of the IgE autoantibodies is ...

Last Updated: 26 Sep 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Bullous Pemphigoid" returned 12 free, full-text review articles on human participants. First 3 results:

Clinical and serological responses following plasmapheresis in bullous pemphigoid: two case reports and a review of the literature.
 

Author(s): Brian Chang, Ashok Tholpady, Richard S P Huang, Elena Nedelcu, Yu Bai

Journal: Blood Transfus. 2014 Apr;12(2):269-75.

 

Last Updated: 16 Jun 2014

Go To URL
Bullous pemphigoid in a 3-month-old infant: case report and literature review of this dermatosis in childhood.
 

Author(s): Eugenio Galdino de Mendonça Reis-Filho, Tainah de Almeida Silva, Luiza Helena de Lima Aguirre, Carmelia Matos Santiago Reis

Journal: An Bras Dermatol. ;88(6):961-5.

 

Bullous pemphigoid is an autoimmune subepidermal blistering dermatosis that is uncommon in childhood. We report a case of a female infant, 3 months old, which presented clinical and laboratory data for the confirmatory diagnosis of bullous pemphigoid. The authors used immunohistochemical ...

Last Updated: 29 Jan 2014

Go To URL
Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.
 

Author(s): Dedee F Murrell, Benjamin S Daniel, Pascal Joly, Luca Borradori, Masayuki Amagai, Takashi Hashimoto, Frédéric Caux, Branka Marinovic, Animesh A Sinha, Michael Hertl, Philippe Bernard, David Sirois, Giuseppe Cianchini, Janet A Fairley, Marcel F Jonkman, Amit G Pandya, David Rubenstein, Detlef Zillikens, Aimee S Payne, David Woodley, Giovanna Zambruno, Valeria Aoki, Carlo Pincelli, Luis Diaz, Russell P Hall, Michael Meurer, Jose M Mascaro, Enno Schmidt, Hiroshi Shimizu, John Zone, Robert Swerlick, Daniel Mimouni, Donna Culton, Jasna Lipozencic, Benjamin Bince, Sergei A Grando, Jean-Claude Bystryn, Victoria P Werth

Journal: J. Am. Acad. Dermatol.. 2012 Mar;66(3):479-85.

 

Our scientific knowledge of bullous pemphigoid (BP) has dramatically progressed in recent years. However, despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few multicenter controlled trials have helped to define effective therapies ...

Last Updated: 20 Feb 2012

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid
 

Status: Recruiting

Condition Summary: Bullous Pemphigoid

 

Last Updated: 3 Dec 2008

Go to URL
Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid
 

Status: Recruiting

Condition Summary: Bullous Pemphigoid

 

Last Updated: 11 Dec 2014

Go to URL
Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
 

Status: Recruiting

Condition Summary: Pemphigoid, Bullous Moderate; Pemphigoid, Bullous Severe

 

Last Updated: 27 Jul 2015

Go to URL